Should biologics for psoriasis be interrupted in the era of COVID-19?
作者信息
Lebwohl Mark, Rivera-Oyola Ryan, Murrell Dedee F
机构信息
Icahn School of Medicine at Mt Sinai Hospital, New York, New York.
Icahn School of Medicine at Mt Sinai Hospital, New York, New York.
出版信息
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
Abstract
摘要
相似文献
1
Should biologics for psoriasis be interrupted in the era of COVID-19?
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
2
Should patients stop their biologic treatment during the COVID-19 pandemic.
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
3
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
4
Asthma, biologics, corticosteroids, and coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.
5
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
6
Guttate psoriasis secondary to COVID-19.
BMJ Case Rep. 2020 Aug 11;13(8):e237367. doi: 10.1136/bcr-2020-237367.
7
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
J Am Acad Dermatol. 2020 Nov;83(5):1523-1526. doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2.
8
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
9
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
10
Psoriasis-COVID 19 Infection: Treatment Options.
Skinmed. 2020 Mar 1;18(2):81-82. eCollection 2020.
引用本文的文献
1
Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.
Life (Basel). 2024 Sep 12;14(9):1157. doi: 10.3390/life14091157.
2
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest.
J Clin Med. 2024 Jun 26;13(13):3713. doi: 10.3390/jcm13133713.
3
Identification of angiogenesis-related genes and molecular subtypes for psoriasis based on random forest algorithm.
Clin Exp Immunol. 2024 Oct 16;218(2):199-212. doi: 10.1093/cei/uxae052.
4
Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.
Psoriasis (Auckl). 2024 May 14;14:29-38. doi: 10.2147/PTT.S451666. eCollection 2024.
5
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.
Dermatol Reports. 2023 Jun 6;16(1):9722. doi: 10.4081/dr.2023.9722. eCollection 2024 Mar 12.
6
Biologics protect psoriasis patients from being exacerbated by COVID-19 infection.
Heliyon. 2024 Jan 14;10(2):e24534. doi: 10.1016/j.heliyon.2024.e24534. eCollection 2024 Jan 30.
7
Psoriasis comorbidity management in the COVID era: a pressing challenge.
Front Microbiol. 2023 Nov 10;14:1294056. doi: 10.3389/fmicb.2023.1294056. eCollection 2023.
8
Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients.
Life (Basel). 2023 May 19;13(5):1219. doi: 10.3390/life13051219.
9
Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies.
Int J Mol Sci. 2023 Mar 29;24(7):6439. doi: 10.3390/ijms24076439.
10
Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review.
Cureus. 2023 Jan 24;15(1):e34141. doi: 10.7759/cureus.34141. eCollection 2023 Jan.
本文引用的文献
1
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31.
2
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.
3
Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.
Br J Dermatol. 2009 Nov;161(5):1190-5. doi: 10.1111/j.1365-2133.2009.09238.x. Epub 2009 May 21.
4
The IL-12 family of cytokines in infection, inflammation and autoimmune disorders.
Inflamm Allergy Drug Targets. 2009 Mar;8(1):40-52. doi: 10.2174/187152809787582507.
Zotero 插件